Compare SRTA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.3M | 407.2M |
| IPO Year | N/A | 2025 |
| Metric | SRTA | AUTL |
|---|---|---|
| Price | $5.53 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $7.81 | ★ $8.50 |
| AVG Volume (30 Days) | 741.8K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $39.27 | $80.32 |
| Revenue Next Year | $8.52 | $53.96 |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $3.85 | $1.18 |
| 52 Week High | $6.02 | $2.70 |
| Indicator | SRTA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 54.85 |
| Support Level | $4.08 | $1.34 |
| Resistance Level | $5.99 | $1.69 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 93.89 | 54.17 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.